News Report | August 3, 2022
Florida Blue Medicare & Prime Therapeutics PBM Pilot Reduced Chronic Opioid Prescriptions By 7%
A pilot opioid prescription reduction program launched by Florida Blue Medicare and its pharmacy benefit manager (PBM) Prime Therapeutics LLC (Prime) reduced new opioid prescription duration and reduced member chronic opioid prescriptions by 7%. The program used predictive modeling based on member claims data and Prime’s opioid registry. Based on the positive results, Prime Therapeutics plans to develop a program that utilizes its Opioid Registry and predictive modeling, with launch anticipated for 2023.
The program emphasized opioid education and safety for Florida Blue Medicare members with new opioid prescriptions and for members with existing opioid prescriptions. To identify the . . .